Jazz Pharmaceuticals (JAZZ) Accumulated Depreciation & Amortization: 2010-2025
Historic Accumulated Depreciation & Amortization for Jazz Pharmaceuticals (JAZZ) over the last 14 years, with Sep 2025 value amounting to $171.2 million.
- Jazz Pharmaceuticals' Accumulated Depreciation & Amortization rose 9.18% to $171.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $671.1 million, marking a year-over-year increase of 16.36%. This contributed to the annual value of $32.8 million for FY2024, which is 7.89% up from last year.
- Per Jazz Pharmaceuticals' latest filing, its Accumulated Depreciation & Amortization stood at $171.2 million for Q3 2025, which was up 2.94% from $166.3 million recorded in Q2 2025.
- In the past 5 years, Jazz Pharmaceuticals' Accumulated Depreciation & Amortization ranged from a high of $171.6 million in Q1 2025 and a low of $70.0 million during Q1 2021.
- In the last 3 years, Jazz Pharmaceuticals' Accumulated Depreciation & Amortization had a median value of $146.3 million in 2024 and averaged $146.3 million.
- Data for Jazz Pharmaceuticals' Accumulated Depreciation & Amortization shows a peak YoY skyrocketed of 32.44% (in 2022) over the last 5 years.
- Jazz Pharmaceuticals' Accumulated Depreciation & Amortization (Quarterly) stood at $85.4 million in 2021, then rose by 26.09% to $107.6 million in 2022, then grew by 23.88% to $133.4 million in 2023, then climbed by 21.45% to $162.0 million in 2024, then rose by 9.18% to $171.2 million in 2025.
- Its Accumulated Depreciation & Amortization was $171.2 million in Q3 2025, compared to $166.3 million in Q2 2025 and $171.6 million in Q1 2025.